From episodes to a lifetime: How AI can enable women’s health brands to build a partnership that lasts

FierceBiotechFor biopharma manufacturing at speed and scale, the future is flexible

FierceBiotechDefinium’s LSD formula produces ‘best data ever seen’ in a pivotal depression trial, CEO says

FierceBiotechHelmed by Sanofi vet, Bionyara emerges with $165M and three licensed I&I assets

Endpoints NewsRegenxbio to resubmit Hunter syndrome gene therapy without new study

Endpoints NewsDefinium reports Phase 3 hit for LSD drug in severe form of depression

Endpoints NewsAbbVie makes $10.9B move for Apogee's long-acting I&I drug candidates

Endpoints NewsA Sanofi alum looks to take on the TL1A field with $165M for Bionyra

BioPharma DiveBionyra brings in $165M for next-generation immune drugs

Endpoints NewsSanofi R&D leader Houman Ashrafian to depart, Paulo Fontoura to take the reins

FierceBiotechSanofi's R&D chief Ashrafian to hit the exit as new CEO seeks to fix stuttering pipeline with Roche alum

Endpoints NewsNura Bio gets $73.8M to advance SARM1 inhibitors for neurodegeneration

BioPharma DiveThe first 14 days: How specialty programs set patients up for success